NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. (NRSN) Company Profile & Overview
Explore NeuroSense Therapeutics Ltd.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
NeuroSense Therapeutics Ltd. (NRSN) Company Profile & Overview
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.